22 results on '"Weber ND"'
Search Results
2. Gene therapy for liver diseases - progress and challenges.
- Author
-
Zabaleta N, Unzu C, Weber ND, and Gonzalez-Aseguinolaza G
- Subjects
- Humans, Genetic Therapy methods, Immunity, Innate, Genetic Vectors, Liver Diseases genetics, Liver Diseases therapy
- Abstract
Gene therapy is poised to revolutionize modern medicine, with seemingly unlimited potential for treating and curing genetic disorders. For otherwise incurable indications, including most inherited metabolic liver disorders, gene therapy provides a realistic therapeutic option. In this Review, we discuss gene supplementation and gene editing involving the use of recombinant adeno-associated virus (rAAV) vectors for the treatment of inherited liver diseases, including updates on several ongoing clinical trials that are producing promising results. Clinical testing has been essential in highlighting many key translational challenges associated with this transformative therapy. In particular, the interaction of a patient's immune system with the vector raises issues of safety and the duration of treatment efficacy. Furthermore, several serious adverse events after the administration of high doses of rAAVs suggest greater involvement of innate immune responses and pre-existing hepatic conditions than initially anticipated. Finally, permanent modification of the host genome associated with rAAV genome integration and gene editing raises concerns about the risk of oncogenicity that require careful evaluation. We summarize the main progress, challenges and pathways forward for gene therapy for liver diseases., (© 2023. Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
3. Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy.
- Author
-
Weber ND, Odriozola L, Ros-Gañán I, García-Porrero G, Salas D, Argemi J, Combal JP, Kishimoto TK, and González-Aseguinolaza G
- Abstract
Background & Aims: Gene therapy using recombinant adeno-associated virus (rAAV) vector carrying multidrug resistance protein 3 (MDR3) coding sequence (AAV8-MDR3) represents a potential curative treatment for progressive familial intrahepatic cholestasis type 3 (PFIC3), which presents in early childhood. However, patients with the severest form of PFIC3 should receive treatment early after detection to prevent irreversible hepatic fibrosis leading ultimately to liver transplantation or death. This represents a challenge for rAAV-based gene therapy because therapeutic efficacy is expected to wane as rAAV genomes are lost owing to hepatocyte division, and the formation of AAV-specific neutralising antibodies precludes re-administration. Here, we tested a strategy of vector re-administration in infant PFIC3 mice with careful evaluation of its oncogenicity - a particular concern surrounding rAAV treatment., Methods: AAV8-MDR3 was re-administered to infant Abcb4
-/- mice 2 weeks after a first dose co-administered with tolerogenic nanoparticles carrying rapamycin (ImmTOR) given at 2 weeks of age. Eight months later, long-term therapeutic efficacy and safety were assessed with special attention paid to the potential oncogenicity of rAAV treatment., Results: Co-administration with ImmTOR mitigated the formation of rAAV-specific neutralising antibodies and enabled an efficacious second administration of AAV8-MDR3, resulting in stable correction of the disease phenotype, including a restoration of bile phospholipid content and healthy liver function, as well as the prevention of liver fibrosis, hepatosplenomegaly, and gallstones. Furthermore, efficacious repeat rAAV administration prevented the appearance of liver malignancies in an animal model highly prone to developing hepatocellular carcinoma., Conclusions: These outcomes provide strong evidence for rAAV redosing through co-administration with ImmTOR, as it resulted in a long-term therapeutic effect in a paediatric liver metabolic disorder, including the prevention of oncogenesis., Impact and Implications: Redosing of gene therapy for inborn hepatobiliary disorders may be essential as effect wanes during hepatocyte division and renewal, particularly in paediatric patients, but the approach may carry long-term risks of liver cancer. Viral vectors carrying a therapeutic gene exerted a durable cure of progressive familial intrahepatic cholestasis type 3 in infant mice and reduced the risk of liver cancer only following a second administration., Competing Interests: NDW, IRG, JPC, and GGA are employees and stockholders of Vivet Therapeutics. TKK is an employee of Selecta Biosciences. All other authors declare no conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details., (© 2023 The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
4. mRNA and gene editing: Late breaking therapies in liver diseases.
- Author
-
Zabaleta N, Torella L, Weber ND, and Gonzalez-Aseguinolaza G
- Subjects
- Animals, CRISPR-Cas Systems, Clustered Regularly Interspaced Short Palindromic Repeats, RNA, Messenger genetics, Gene Editing methods, Liver Diseases genetics, Liver Diseases therapy
- Abstract
The efficient delivery of RNA molecules to restore the expression of a missing or inadequately functioning protein in a target cell and the intentional specific modification of the host genome using engineered nucleases represent therapeutic concepts that are revolutionizing modern medicine. The initiation of several clinical trials using these approaches to treat metabolic liver disorders as well as the recently reported remarkable results obtained by patients with transthyretin amyloidosis highlight the advances in this field and show the potential of these therapies to treat these diseases safely and efficaciously. These advances have been possible due, firstly, to significant improvements made in RNA chemistry that increase its stability and prevent activation of the innate immune response and, secondly, to the development of very efficient liver-targeted RNA delivery systems. In parallel, the breakout of CRISPR/CRISPR-associated 9-based technology in the gene editing field has marked a turning point in in vivo modification of the cellular genome with therapeutic purposes, which can be based on gene supplementation, correction, or silencing. In the coming years we are likely to witness the therapeutic potential of these two strategies both separately and in combination. In this review we summarize the preclinical data obtained in animal models treated with mRNA as a therapeutic agent and discuss the different gene editing strategies applied to the treatment of liver diseases, highlighting both their therapeutic efficacy as well as safety concerns., (© 2022 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.)
- Published
- 2022
- Full Text
- View/download PDF
5. A minimal bile salt excretory pump promoter allows bile acid-driven physiological regulation of transgene expression from a gene therapy vector.
- Author
-
Martínez-García J, Molina M, Odriozola L, Molina A, González-Aseguinolaza G, Weber ND, and Smerdou C
- Abstract
Background: Bile acid (BA) homeostasis is mainly regulated by bile salt excretory pump (BSEP), a hepatocyte transporter that transfers BAs to the bile. BSEP expression is regulated by BA levels through activation of farnesoid X receptor transcription factor, which binds to the inverted repeat (IR-1) element in the BSEP promoter. Gene therapy of cholestatic diseases could benefit from using vectors carrying endogenous promoters physiologically regulated by BAs, however their large size limits this approach, especially when using adeno-associated viral vector (AAV) vectors., Results: We evaluated the functionality and BA-mediated regulation of minimal versions of human and mouse BSEP promoters containing IR-1 using AAV vectors expressing luciferase. Unexpectedly, a minimal mouse BSEP promoter (imPr) showed higher BA-mediated expression and inducibility than a minimal human promoter (ihPr) or than full-length BSEP promoters in human hepatic cells. In addition, in mice receiving an AAV8 vector carrying imPr promoter-driven luciferase expression was efficiently regulated by administration of a BA-enriched diet. Interestingly, this vector also expressed significantly higher luciferase levels in Abcb4
-/- mice, which have high levels of BAs, compared to wild type mice, or to mice receiving a vector containing the luciferase gene downstream of the constitutive alpha-1 antitrypsin promoter. In contrast, the AAV vector containing ihPr showed very low luciferase expression with no inducibility. Finally, we optimized imPr by adding three IR-1 repeats at its 5' end. This new promoter provided higher levels of luciferase than imPr both in vitro and in vivo., Conclusions: The imPr could represent a useful tool for gene therapy approaches in which physiological BA regulation is desired., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
6. Gene Therapy for Acquired and Genetic Cholestasis.
- Author
-
Martínez-García J, Molina A, González-Aseguinolaza G, Weber ND, and Smerdou C
- Abstract
Cholestatic diseases can be caused by the dysfunction of transporters involved in hepatobiliary circulation. Although pharmacological treatments constitute the current standard of care for these diseases, none are curative, with liver transplantation being the only long-term solution for severe cholestasis, albeit with many disadvantages. Liver-directed gene therapy has shown promising results in clinical trials for genetic diseases, and it could constitute a potential new therapeutic approach for cholestatic diseases. Many preclinical gene therapy studies have shown positive results in animal models of both acquired and genetic cholestasis. The delivery of genes that reduce apoptosis or fibrosis or improve bile flow has shown therapeutic effects in rodents in which cholestasis was induced by drugs or bile duct ligation. Most studies targeting inherited cholestasis, such as progressive familial intrahepatic cholestasis (PFIC), have focused on supplementing a correct version of a mutated gene to the liver using viral or non-viral vectors in order to achieve expression of the therapeutic protein. These strategies have generated promising results in treating PFIC3 in mouse models of the disease. However, important challenges remain in translating this therapy to the clinic, as well as in developing gene therapy strategies for other types of acquired and genetic cholestasis.
- Published
- 2022
- Full Text
- View/download PDF
7. Comment on "Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4 -/- mouse model of PFIC3".
- Author
-
Weber ND, Martínez-García J, and González-Aseguinolaza G
- Subjects
- Animals, Humans, Mice, Phenotype, RNA, Messenger genetics, Cholestasis, Intrahepatic genetics
- Abstract
Competing Interests: Conflict of interest NDW and GGA are employees and stockholders of Vivet Therapeutics. All other authors declare no conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.
- Published
- 2022
- Full Text
- View/download PDF
8. Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model.
- Author
-
Kaiser RA, Weber ND, Trigueros-Motos L, Allen KL, Martinez M, Cao W, VanLith CJ, Hillin LG, Douar A, González-Aseguinolaza G, Aldabe R, and Lillegard JB
- Subjects
- Animals, Cell Line, DNA, Recombinant administration & dosage, Disease Models, Animal, Female, Genetic Vectors genetics, Hair Color, Humans, Injections, Intravenous, Liver enzymology, Male, Mice, Mice, Inbred C57BL, Phenylalanine blood, Phenylalanine Hydroxylase immunology, Phenylalanine Hydroxylase metabolism, Transduction, Genetic methods, Dependovirus genetics, Genetic Therapy methods, Genetic Vectors administration & dosage, Phenylalanine Hydroxylase genetics, Phenylketonurias therapy
- Abstract
Phenylketonuria (PKU) is the most common inborn error of metabolism of the liver, and results from mutations of both alleles of the phenylalanine hydroxylase gene (PAH). As such, it is a suitable target for gene therapy via gene delivery with a recombinant adeno-associated virus (AAV) vector. Here we use the synthetic AAV vector Anc80 via systemic administration to deliver a functional copy of a codon-optimized human PAH gene, with or without an intron spacer, to the Pah
enu2 mouse model of PKU. Dose-dependent transduction of the liver and expression of PAH mRNA were present with both vectors, resulting in significant and durable reduction of circulating phenylalanine, reaching near control levels in males. Coat color of treated Pahenu2 mice reflected an increase in pigmentation from brown to the black color of control animals, further indicating functional restoration of phenylalanine metabolism and its byproduct melanin. There were no adverse effects associated with administration of AAV up to 5 × 1012 VG/kg, the highest dose tested. Only minor and/or transient variations in some liver enzymes were observed in some of the AAV-dosed animals which were not associated with pathology findings in the liver. Finally, there was no impact on cell turnover or apoptosis as evaluated by Ki-67 and TUNEL staining, further supporting the safety of this approach. This study demonstrates the therapeutic potential of AAV Anc80 to safely and durably cure PKU in a mouse model, supporting development for clinical consideration., (© 2021 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.)- Published
- 2021
- Full Text
- View/download PDF
9. Novel vectors and approaches for gene therapy in liver diseases.
- Author
-
Maestro S, Weber ND, Zabaleta N, Aldabe R, and Gonzalez-Aseguinolaza G
- Abstract
Gene therapy is becoming an increasingly valuable tool to treat many genetic diseases with no or limited treatment options. This is the case for hundreds of monogenic metabolic disorders of hepatic origin, for which liver transplantation remains the only cure. Furthermore, the liver contains 10-15% of the body's total blood volume, making it ideal for use as a factory to secrete proteins into the circulation. In recent decades, an expanding toolbox has become available for liver-directed gene delivery. Although viral vectors have long been the preferred approach to target hepatocytes, an increasing number of non-viral vectors are emerging as highly efficient vehicles for the delivery of genetic material. Herein, we review advances in gene delivery vectors targeting the liver and more specifically hepatocytes, covering strategies based on gene addition and gene editing, as well as the exciting results obtained with the use of RNA as a therapeutic molecule. Moreover, we will briefly summarise some of the limitations of current liver-directed gene therapy approaches and potential ways of overcoming them., Competing Interests: NDW and GGA are Vivet Therapeutics employees and hold stock of the company. Please refer to the accompanying ICMJE disclosure forms for further details., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
10. CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice.
- Author
-
Stone D, Long KR, Loprieno MA, De Silva Feelixge HS, Kenkel EJ, Liley RM, Rapp S, Roychoudhury P, Nguyen T, Stensland L, Colón-Thillet R, Klouser LM, Weber ND, Le C, Wagoner J, Goecker EA, Li AZ, Eichholz K, Corey L, Tyrrell DL, Greninger AL, Huang ML, Polyak SJ, Aubert M, Sagartz JE, and Jerome KR
- Abstract
Chronic hepatitis B virus (HBV) infection is a major public health problem. New treatment approaches are needed because current treatments do not target covalently closed circular DNA (cccDNA), the template for HBV replication, and rarely clear the virus. We harnessed adeno-associated virus (AAV) vectors and CRISPR- Staphylococcus aureus ( Sa )Cas9 to edit the HBV genome in liver-humanized FRG mice chronically infected with HBV and receiving entecavir. Gene editing was detected in livers of five of eight HBV-specific AAV- Sa Cas9-treated mice, but not control mice, and mice with detectable HBV gene editing showed higher levels of Sa Cas9 delivery to HBV
+ human hepatocytes than those without gene editing. HBV-specific AAV- Sa Cas9 therapy significantly improved survival of human hepatocytes, showed a trend toward decreasing total liver HBV DNA and cccDNA, and was well tolerated. This work provides evidence for the feasibility and safety of in vivo gene editing for chronic HBV infections, and it suggests that with further optimization, this approach may offer a plausible way to treat or even cure chronic HBV infections., Competing Interests: The authors declare no competing interests., (© 2020 The Author(s).)- Published
- 2020
- Full Text
- View/download PDF
11. Gene therapy for progressive familial intrahepatic cholestasis type 3 in a clinically relevant mouse model.
- Author
-
Weber ND, Odriozola L, Martínez-García J, Ferrer V, Douar A, Bénichou B, González-Aseguinolaza G, and Smerdou C
- Subjects
- ATP Binding Cassette Transporter, Subfamily B genetics, Animals, Cell Line, Tumor, Cholestasis, Intrahepatic genetics, Dependovirus genetics, Disease Models, Animal, Female, Genetic Vectors administration & dosage, Genetic Vectors genetics, HEK293 Cells, Humans, Male, Mice, Mice, Knockout, Recombinant Proteins genetics, Sex Factors, Treatment Outcome, ATP Binding Cassette Transporter, Subfamily B deficiency, Cholestasis, Intrahepatic therapy, Genetic Therapy methods
- Abstract
Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a rare monogenic disease caused by mutations in the ABCB4 gene, resulting in a reduction in biliary phosphatidylcholine. Reduced biliary phosphatidylcholine cannot counteract the detergent effects of bile salts, leading to cholestasis, cholangitis, cirrhosis and ultimately liver failure. Here, we report results from treating two- or five-week-old Abcb4
-/- mice with an AAV vector expressing human ABCB4, resulting in significant decreases of PFIC3 disease biomarkers. All male mice achieved a sustained therapeutic effect up through 12 weeks, but the effect was achieved in only 50% of females. However, two-week-old females receiving a second inoculation three weeks later maintained the therapeutic effect. Upon sacrifice, markers of PFIC3 disease such as, hepatosplenomegaly, biliary phosphatidylcholine and liver histology were significantly improved. Thus, AAV-mediated gene therapy successfully prevented PFIC3 symptoms in a clinically relevant mouse model, representing a step forward in improving potential therapy options for PFIC3 patients.- Published
- 2019
- Full Text
- View/download PDF
12. Own-Choice Marriage and Fertility in Turkey.
- Author
-
Manglos-Weber ND and Weinreb AA
- Abstract
Goode's foundational work on the fertility transition identified own-choice marriage as a factor driving fertility decline, part of a widening repertoire of choice pertaining to marriage and childbearing. Yet research supporting this connection in today's transitional societies is scarce and somewhat contradictory, and it is unclear how other marital traditions, such as consanguineous marriage, shape this relationship. This study evaluates Goode's theorized connection using pooled Demographic and Health Survey data from Turkey, comparing children ever born, use of contraception, and parity progression across four types of marriage: own-choice and arranged marriage; and marriage to a cousin versus an unrelated spouse. Results are largely consistent with the idea that a move towards own-choice marriage reflects a widening repertoire of choice that also leads to fertility decline. However, they also show that hybrid models like own-choice marriage to a cousin tempers these effects.
- Published
- 2017
- Full Text
- View/download PDF
13. Digital detection of endonuclease mediated gene disruption in the HIV provirus.
- Author
-
Sedlak RH, Liang S, Niyonzima N, De Silva Feelixge HS, Roychoudhury P, Greninger AL, Weber ND, Boissel S, Scharenberg AM, Cheng A, Magaret A, Bumgarner R, Stone D, and Jerome KR
- Subjects
- HEK293 Cells, Humans, Exodeoxyribonucleases chemistry, HIV-1 genetics, INDEL Mutation, Polymerase Chain Reaction methods, Proviruses genetics
- Abstract
Genome editing by designer nucleases is a rapidly evolving technology utilized in a highly diverse set of research fields. Among all fields, the T7 endonuclease mismatch cleavage assay, or Surveyor assay, is the most commonly used tool to assess genomic editing by designer nucleases. This assay, while relatively easy to perform, provides only a semi-quantitative measure of mutation efficiency that lacks sensitivity and accuracy. We demonstrate a simple droplet digital PCR assay that quickly quantitates a range of indel mutations with detection as low as 0.02% mutant in a wild type background and precision (≤6%CV) and accuracy superior to either mismatch cleavage assay or clonal sequencing when compared to next-generation sequencing. The precision and simplicity of this assay will facilitate comparison of gene editing approaches and their optimization, accelerating progress in this rapidly-moving field.
- Published
- 2016
- Full Text
- View/download PDF
14. AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication.
- Author
-
Weber ND, Stone D, Sedlak RH, De Silva Feelixge HS, Roychoudhury P, Schiffer JT, Aubert M, and Jerome KR
- Subjects
- Antiviral Agents chemistry, Base Sequence, Cell Line, Tumor, DNA Breaks, Double-Stranded, DNA End-Joining Repair, DNA, Viral genetics, Dependovirus genetics, Endonucleases chemistry, Endonucleases metabolism, Gene Products, pol antagonists & inhibitors, Gene Products, pol chemistry, Genetic Vectors, HEK293 Cells, Hepatitis B virus chemistry, Hepatocytes virology, Humans, Molecular Sequence Data, Protein Engineering, Trans-Activators antagonists & inhibitors, Trans-Activators chemistry, Viral Core Proteins antagonists & inhibitors, Viral Core Proteins chemistry, Viral Regulatory and Accessory Proteins, Virus Replication genetics, Zinc Fingers genetics, Antiviral Agents metabolism, Endonucleases genetics, Gene Products, pol genetics, Gene Targeting, Hepatitis B virus genetics, Trans-Activators genetics, Viral Core Proteins genetics
- Abstract
Despite an existing effective vaccine, hepatitis B virus (HBV) remains a major public health concern. There are effective suppressive therapies for HBV, but they remain expensive and inaccessible to many, and not all patients respond well. Furthermore, HBV can persist as genomic covalently closed circular DNA (cccDNA) that remains in hepatocytes even during otherwise effective therapy and facilitates rebound in patients after treatment has stopped. Therefore, the need for an effective treatment that targets active and persistent HBV infections remains. As a novel approach to treat HBV, we have targeted the HBV genome for disruption to prevent viral reactivation and replication. We generated 3 zinc finger nucleases (ZFNs) that target sequences within the HBV polymerase, core and X genes. Upon the formation of ZFN-induced DNA double strand breaks (DSB), imprecise repair by non-homologous end joining leads to mutations that inactivate HBV genes. We delivered HBV-specific ZFNs using self-complementary adeno-associated virus (scAAV) vectors and tested their anti-HBV activity in HepAD38 cells. HBV-ZFNs efficiently disrupted HBV target sites by inducing site-specific mutations. Cytotoxicity was seen with one of the ZFNs. scAAV-mediated delivery of a ZFN targeting HBV polymerase resulted in complete inhibition of HBV DNA replication and production of infectious HBV virions in HepAD38 cells. This effect was sustained for at least 2 weeks following only a single treatment. Furthermore, high specificity was observed for all ZFNs, as negligible off-target cleavage was seen via high-throughput sequencing of 7 closely matched potential off-target sites. These results show that HBV-targeted ZFNs can efficiently inhibit active HBV replication and suppress the cellular template for HBV persistence, making them promising candidates for eradication therapy.
- Published
- 2014
- Full Text
- View/download PDF
15. DNA cleavage enzymes for treatment of persistent viral infections: recent advances and the pathway forward.
- Author
-
Weber ND, Aubert M, Dang CH, Stone D, and Jerome KR
- Subjects
- Animals, DNA Cleavage, Humans, DNA, Viral genetics, DNA, Viral metabolism, Virus Diseases therapy, Virus Latency, Virus Physiological Phenomena
- Abstract
Treatment for most persistent viral infections consists of palliative drug options rather than curative approaches. This is often because long-lasting viral DNA in infected cells is not affected by current antivirals, providing a source for viral persistence and reactivation. Targeting latent viral DNA itself could therefore provide a basis for novel curative strategies. DNA cleavage enzymes can be used to induce targeted mutagenesis of specific genes, including those of exogenous viruses. Although initial in vitro and even in vivo studies have been carried out using DNA cleavage enzymes targeting various viruses, many questions still remain concerning the feasibility of these strategies as they transition into preclinical research. Here, we review the most recent findings on DNA cleavage enzymes for human viral infections, consider the most relevant animal models for several human viral infections, and address issues regarding safety and enzyme delivery. Results from well-designed in vivo studies will ideally provide answers to the most urgent remaining questions, and allow continued progress toward clinical application., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
16. TALENs targeting HBV: designer endonuclease therapies for viral infections.
- Author
-
Weber ND, Stone D, and Jerome KR
- Subjects
- Animals, Humans, DNA, Circular genetics, DNA, Viral genetics, Deoxyribonucleases genetics, Deoxyribonucleases physiology, Hepatitis B virus genetics, Hepatitis B virus physiology, Virus Replication
- Published
- 2013
- Full Text
- View/download PDF
17. Targeted DNA mutagenesis for the cure of chronic viral infections.
- Author
-
Schiffer JT, Aubert M, Weber ND, Mintzer E, Stone D, and Jerome KR
- Subjects
- Animals, DNA, Viral metabolism, Humans, Viruses drug effects, Viruses metabolism, DNA, Viral genetics, Endonucleases antagonists & inhibitors, Mutagenesis, Virus Diseases drug therapy, Virus Diseases virology, Viruses genetics
- Abstract
Human immunodeficiency virus type 1 (HIV-1), hepatitis B virus (HBV), and herpes simplex virus (HSV) have been incurable to date because effective antiviral therapies target only replicating viruses and do not eradicate latently integrated or nonreplicating episomal viral genomes. Endonucleases that can target and cleave critical regions within latent viral genomes are currently in development. These enzymes are being engineered with high specificity such that off-target binding of cellular DNA will be absent or minimal. Imprecise nonhomologous-end-joining (NHEJ) DNA repair following repeated cleavage at the same critical site may permanently disrupt translation of essential viral proteins. We discuss the benefits and drawbacks of three types of DNA cleavage enzymes (zinc finger endonucleases, transcription activator-like [TAL] effector nucleases [TALENs], and homing endonucleases [also called meganucleases]), the development of delivery vectors for these enzymes, and potential obstacles for successful treatment of chronic viral infections. We then review issues regarding persistence of HIV-1, HBV, and HSV that are relevant to eradication with genome-altering approaches.
- Published
- 2012
- Full Text
- View/download PDF
18. PEGylated poly(ethylene imine) copolymer-delivered siRNA inhibits HIV replication in vitro.
- Author
-
Weber ND, Merkel OM, Kissel T, and Muñoz-Fernández MÁ
- Subjects
- Cell Line, Tumor, HIV physiology, Humans, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear virology, Polyethyleneimine administration & dosage, Virus Replication physiology, Anti-HIV Agents administration & dosage, Drug Delivery Systems methods, HIV drug effects, Polyethylene Glycols administration & dosage, Polyethyleneimine analogs & derivatives, RNA, Small Interfering administration & dosage, Virus Replication drug effects
- Abstract
RNA interference is increasingly being utilized for the specific targeting and down-regulation of disease-causing genes, including targeting viral infections such as HIV. T lymphocytes, the primary target for HIV, are very difficult to treat with gene therapy applications such as RNA interference because of issues with drug delivery. To circumvent these problems, we investigated poly(ethylene imine) (PEI) as a method of improving transfection efficiency of siRNA to T lymphocytes. Additionally, polyethylene glycol (PEG) moieties were engrafted to the PEI polymers with the goals of improving stability and reducing cytotoxicity. Initial studies on PEG-PEI/siRNA polyplex formation, size and their interaction with cell membranes demonstrated their feasibility as drug delivery agents. Assays with lymphocytes revealed low cytotoxicity profiles of the polyplexes at pharmacologically relevant concentrations with PEGylated copolymers obtaining the best results. Successful transfection of a T cell line or primary T cells with siRNA was observed via flow cytometry and confocal microscopy. Finally, the biological effect of copolymer-delivered siRNA was measured. Of particular significance, siRNA targeted to the HIV gene nef and delivered by one of the PEG-PEI copolymers in repetitive treatments every 2-3 days was observed to inhibit HIV replication to the same extent as azidothymidine over the course of 15 days., (Copyright © 2011 Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
19. Carbosilane dendrimers to transfect human astrocytes with small interfering RNA targeting human immunodeficiency virus.
- Author
-
Jiménez JL, Clemente MI, Weber ND, Sanchez J, Ortega P, de la Mata FJ, Gómez R, García D, López-Fernández LA, and Muñoz-Fernández MA
- Subjects
- AIDS Dementia Complex genetics, AIDS Dementia Complex pathology, AIDS Dementia Complex therapy, Adult, Animals, Anti-HIV Agents therapeutic use, Astrocytes physiology, Blood-Brain Barrier cytology, Blood-Brain Barrier physiology, Blood-Brain Barrier virology, Cattle, Cells, Cultured, Child, Drug Discovery, Gene Silencing, Gene Transfer Techniques, Humans, Targeted Gene Repair, Astrocytes virology, Dendrimers toxicity, Genetic Vectors toxicity, HIV genetics, RNA, Small Interfering, Silanes toxicity, Virus Replication genetics
- Abstract
Background: HIV infection of the CNS is the principle cause of HIV-associated dementia in adults and encephalopathy in children. Gene therapy techniques such as small interfering RNA (siRNA) possess great potential in drug development, but first they must overcome the key obstacle of reaching the interior of the affected cells. A successful delivery vector for anti-HIV drugs that is capable of crossing the blood-brain barrier (BBB) could provide a way of addressing this issue. Non-viral vectors such as dendrimers offer a means for effectively delivering and transfecting siRNA to the target cells., Objective: To evaluate the application of gene therapy for reducing HIV replication in human astrocytes., Methods: We used the 2G-NN16 amino-terminated carbosilane dendrimer as a method for delivering siRNA to HIV-infected human astrocytes. We tested the cytotoxicity in human astrocytoma cells caused by 2G-NN16 and dendriplexes formed with siRNA (siRNA/2G-NN16) by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium-bromide (MTT) and lactate dehydrogenase assays. The ability to transfect human astrocytes with siRNA/2G-NN16 dendriplexes was tested by flow cytometry and immunofluorescence microscopy. To assess the potential capability of siRNA/2G-NN16 dendriplexes for crossing the BBB, we used an in vitro transcytosis assay with bovine brain microvascular endothelial cells. HIV-1 inhibition assays using 2G-NN16 and siRNA/2G-NN16 dendriplexes were determined by quantification of the viral load from culture supernatants of the astrocytes., Results: A gradual time-controlled degradation of the 2G-NN16 dendrimer and liberation of its siRNA cargo between 12 and 24 hours was observed via gel electrophoresis. There was no cytotoxicity in HIV-infected or non-infected human astrocytoma cells when treated with up to 24 microg/mL of 2G-NN16 dendrimer or siRNA/2G-NN16 dendriplexes, and siRNA/2G-NN16 dendriplexes were seen to successfully transfect human astrocytes even after crossing an in vitro BBB model. More interestingly, transfected siRNA was observed to exert a biologic effect, as dendriplexes were shown to down-regulate the housekeeping gene GAPDH and to reduce replication of HIV-1 strains X4-HIV NL4-3 and R5-HIV BaL in human astrocytes., Conclusions: The 2G-NN16 dendrimer successfully delivers and transfects siRNA to HIV-infected human astrocytes and achieves gene silencing without causing cytotoxicity.
- Published
- 2010
- Full Text
- View/download PDF
20. Gene therapy in HIV-infected cells to decrease viral impact by using an alternative delivery method.
- Author
-
Gonzalo T, Clemente MI, Chonco L, Weber ND, Díaz L, Serramía MJ, Gras R, Ortega P, de la Mata FJ, Gómez R, Lopez-Fernández LA, Muñoz-Fernández MA, and Jiménez JL
- Subjects
- Astrocytes metabolism, Cell Line, Tumor, Dendrimers toxicity, Dendritic Cells immunology, Dendritic Cells metabolism, Flow Cytometry, HIV Core Protein p24 genetics, HIV Core Protein p24 metabolism, HIV-1 genetics, Humans, Lymphocytes immunology, Lymphocytes metabolism, Macrophages immunology, Macrophages metabolism, Oligoribonucleotides, Antisense, RNA, Small Interfering, RNA, Viral, Dendrimers chemistry, Genetic Therapy, HIV-1 physiology, Transfection
- Abstract
The ability of dendrimer 2G-[Si{O(CH(2))(2)N(Me)(2) (+)(CH(2))(2)NMe(3) (+)(I(-))(2)}](8) (NN16) to transfect a wide range of cell types, as well as the possible biomedical application in direct or indirect inhibition of HIV replication, was investigated. Cells implicated in HIV infection such as primary peripheral blood mononuclear cells (PBMC) and immortalized suspension cells (lymphocytes), primary macrophages and dendritic cells, and immortalized adherent cells (astrocytes and trophoblasts) were analyzed. Dendrimer toxicity was evaluated by mitochondrial activity, cell membrane rupture, release of lactate dehydrogenase, erythrocyte hemolysis, and the effect on global gene expression profiles using whole-genome human microarrays. Cellular uptake of genetic material was determined using flow cytometry and confocal microscopy. Transfection efficiency and gene knockdown was investigated using dendrimer-delivered antisense oligonucleotides and small interfering RNA (siRNA). Very little cytotoxicity was detected in a variety of cells relevant to HIV infection and erythrocytes after NN16 dendrimer treatment. Imaging of cellular uptake showed high transfection efficiency of genetic material in all cells tested. Interestingly, NN16 further enhanced the reduction of HIV protein 24 antigen release by antisense oligonucleotides due to improved transfection efficiency. Finally, the dendrimer complexed with siRNA exhibited therapeutic potential by specifically inhibiting cyclooxygenase-2 gene expression in HIV-infected nervous system cells. NN16 dendrimers demonstrated the ability to transfect genetic material into a vast array of cells relevant to HIV pathology, combining high efficacy with low toxicity. These results suggest that NN16 dendrimers have the potential to be used as a versatile non-viral vector for gene therapy against HIV infection.
- Published
- 2010
- Full Text
- View/download PDF
21. In vitro virucidal effects of Allium sativum (garlic) extract and compounds.
- Author
-
Weber ND, Andersen DO, North JA, Murray BK, Lawson LD, and Hughes BG
- Subjects
- Animals, Chlorocebus aethiops, DNA Viruses drug effects, Disulfides, HeLa Cells, Humans, Plant Extracts toxicity, RNA Viruses drug effects, Sulfinic Acids pharmacology, Vero Cells, Antiviral Agents pharmacology, Garlic chemistry, Plant Extracts pharmacology, Plants, Medicinal
- Abstract
Garlic (Allium sativum) has been shown to have antiviral activity, but the compounds responsible have not been identified. Using direct pre-infection incubation assays, we determined the in vitro virucidal effects of fresh garlic extract, its polar fraction, and the following garlic associated compounds: diallyl thiosulfinate (allicin), allyl methyl thiosulfinate, methyl allyl thiosulfinate, ajoene, alliin, deoxyalliin, diallyl disulfide, and diallyl trisulfide. Activity was determined against selected viruses including, herpes simplex virus type 1, herpes simplex virus type 2, parainfluenza virus type 3, vaccinia virus, vesicular stomatitis virus, and human rhinovirus type 2. The order for virucidal activity generally was: ajoene > allicin > allyl methyl thiosulfinate > methyl allyl thiosulfinate. Ajoene was found in oil-macerates of garlic but not in fresh garlic extracts. No activity was found for the garlic polar fraction, alliin, deoxyalliin, diallyl disulfide, or diallyl trisulfide. Fresh garlic extract, in which thiosulfinates appeared to be the active components, was virucidal to each virus tested. The predominant thiosulfinate in fresh garlic extract was allicin. Lack of reduction in yields of infectious virus indicated undetectable levels of intracellular antiviral activity for either allicin or fresh garlic extract. Furthermore, concentrations that were virucidal were also toxic to HeLa and Vero cells. Virucidal assay results were not influenced by cytotoxicity since the compounds were diluted below toxic levels prior to assaying for infectious virus. These results indicate that virucidal activity and cytotoxicity may have depended upon the viral envelope and cell membrane, respectively. However, activity against non-enveloped virus may have been due to inhibition of viral adsorption or penetration.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1992
- Full Text
- View/download PDF
22. In vitro virucidal activity of selected anthraquinones and anthraquinone derivatives.
- Author
-
Andersen DO, Weber ND, Wood SG, Hughes BG, Murray BK, and North JA
- Subjects
- Animals, Anthracenes, Anthraquinones chemistry, Emodin analogs & derivatives, HeLa Cells, Humans, Perylene pharmacology, Polysorbates pharmacology, Respirovirus drug effects, Simplexvirus drug effects, Vaccinia virus drug effects, Vero Cells, Vesicular stomatitis Indiana virus drug effects, Anthraquinones pharmacology, Antiviral Agents pharmacology, Emodin pharmacology, Perylene analogs & derivatives, Viruses drug effects
- Abstract
Anthraquinones and anthraquinone derivatives were characterized for their antiviral and virucidal activities against viruses representing several taxonomic groups. One of these compounds, hypericin, had activity against vesicular stomatitis virus, herpes simplex virus types 1 and 2, parainfluenza virus, and vaccinia virus (from 0.5 to 3.8 log10 reductions in infectivity) at concentrations of less than 1 microgram/ml as determined by a direct pre-infection incubation assay. Human rhinovirus was not sensitive to hypericin at concentrations up to 10 micrograms/ml. Addition of small amounts of Tween-80 to solutions containing hypericin enhanced, by up to 2.6 log10, hypericin's virucidal activity. Anthraquinones and anthraquinone derivatives with the hydroxyl and alkyl substitution pattern of emodin (i.e. emodin, emodin anthrone, emodin bianthrone and hypericin) were active against the enveloped viruses tested. The following general pattern of activity was found: hypericin greater than emodin bianthrone greater than emodin anthrone greater than emodin. Chrysophanic acid, aloe-emodin, and sennosides A and B did not possess activity against any of the viruses tested.
- Published
- 1991
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.